{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:13:33Z","timestamp":1790748813127,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.ando.2013.03.004","type":"journal-article","created":{"date-parts":[[2013,4,6]],"date-time":"2013-04-06T03:15:52Z","timestamp":1365218152000},"page":"79-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["R\u00f4le de l\u2019Activine A et de la Myostatine dans la cachexie canc\u00e9reuse"],"prefix":"10.1016","volume":"74","author":[{"given":"Jean-Paul","family":"Thissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Loumaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2013.03.004_bib0005","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2013.03.004_bib0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.ando.2013.03.004_bib0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanisms of cancer cachexia","volume":"89","author":"Tisdale","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ando.2013.03.004_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/JOE-08-0549","article-title":"The biology of activin: recent advances in structure, regulation and function","volume":"202","author":"Xia","year":"2009","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ando.2013.03.004_bib0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1507\/endocrj.KR-110","article-title":"Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer","volume":"55","author":"Tsuchida","year":"2008","journal-title":"Endocr J"},{"key":"10.1016\/j.ando.2013.03.004_bib0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member","volume":"387","author":"McPherron","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ando.2013.03.004_bib0035","doi-asserted-by":"crossref","first-page":"E157","DOI":"10.1152\/ajpendo.00193.2009","article-title":"Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin","volume":"297","author":"Gilson","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ando.2013.03.004_bib0040","doi-asserted-by":"crossref","first-page":"8817","DOI":"10.1073\/pnas.91.19.8817","article-title":"Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice","volume":"91","author":"Matzuk","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ando.2013.03.004_bib0045","first-page":"534","article-title":"Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice","volume":"10","author":"Coerver","year":"1996","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ando.2013.03.004_bib0050","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1210\/endo.141.7.7535","article-title":"Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice","volume":"141","author":"Cipriano","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.ando.2013.03.004_bib0055","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/molehr\/gam055","article-title":"Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein","volume":"13","author":"Li","year":"2007","journal-title":"Mol Hum Reprod"},{"key":"10.1016\/j.ando.2013.03.004_bib0060","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1210\/me.2007-0147","article-title":"SMAD3\u00a0regulates gonadal tumorigenesis","volume":"21","author":"Li","year":"2007","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ando.2013.03.004_bib0065","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1126\/science.1069525","article-title":"Induction of cachexia in mice by systemically administered myostatin","volume":"296","author":"Zimmers","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ando.2013.03.004_bib0070","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ando.2013.03.004_bib0075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/BJ20112024","article-title":"Myostatin is a novel tumoral factor that induces cancer cachexia","volume":"446","author":"Lokireddy","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.ando.2013.03.004_bib0080","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.bbrc.2009.12.123","article-title":"Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia","volume":"391","author":"Benny Klimek","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ando.2013.03.004_bib0085","doi-asserted-by":"crossref","first-page":"R716","DOI":"10.1152\/ajpregu.00121.2011","article-title":"Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice","volume":"301","author":"Murphy","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.ando.2013.03.004_bib0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13539-011-0049-z","article-title":"Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance","volume":"3","author":"Busquets","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.ando.2013.03.004_bib0095","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1210\/edrv.22.6.0450","article-title":"Activins and inhibins in endocrine and other tumors","volume":"22","author":"Risbridger","year":"2001","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2013.03.004_bib0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10585-006-9010-5","article-title":"Activin A circulating levels in patients with bone metastasis from breast or prostate cancer","volume":"23","author":"Leto","year":"2006","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ando.2013.03.004_bib0105","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1245\/s10434-011-1720-5","article-title":"Changes in myostatin signaling in non-weight-losing cancer patients","volume":"19","author":"Aversa","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ando.2013.03.004_bib0110","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/annonc\/mds068","article-title":"Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy","volume":"23","author":"Terpos","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ando.2013.03.004_bib0125","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mus.23539","article-title":"A single ascending-dose study of muscle regulator ACE-031\u00a0in healthy volunteers","volume":"47","author":"Attie","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ando.2013.03.004_bib0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1517\/13543784.2013.738666","article-title":"Activin receptor antagonists for cancer-related anemia and bone disease","volume":"22","author":"Fields","year":"2013","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426613000310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426613000310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:46:15Z","timestamp":1757717175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426613000310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0003426613000310"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2013.03.004","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"R\u00f4le de l\u2019Activine A et de la Myostatine dans la cachexie canc\u00e9reuse","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2013.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}